April 09, 2020 04:00 PM Eastern Daylight Time ROCKVILLE, Md. & PROVIDENCE, R.I. & GOLDEN, Colo.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study ...
Immunomic Therapeutics Announces Completion of Pre-IND Meeting with US FDA for ITI-1001, a Vaccine for the Treatment of GBM
- Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM) - March 03, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held ...
Immunomic Therapeutics’ Collaborator, University of Florida Presents New Clinical Data from ATTAC-II Study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting
Nov. 20, 2019 ROCKVILLE, MD – Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD, ...
November 04, 2019 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that ...
Immunomic Therapeutics to Present at the First International Symposium on Merkel Cell Carcinoma 2019
Data demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal ...
Discussion of UNITE platform as applied in cancer immunotherapy BOSTON--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today a presentation at the Precision Lung Cancer World R&D Summit in Boston. On Tuesday, ...
Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM
- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) ...
Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. ...
July 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as ...
June 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. ...
April 04, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C. ...
Immunomic Therapeutics Announces Late-Breaking Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
February 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer ...